Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Determinants of Resistance to Endocrine Therapy and CDK4/6 Inhibitor in HR+ MBC
NCT03439735Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2018
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2018; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03439735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439735.